CSLClinical Trials•businesswire•September 16, 2025 at 06:00 AM

VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment

Sentiment:Neutral (55)

Summary

(NYSE:CSL) LEIDEN, Netherlands--(BUSINESS WIRE)--VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational blood coagulation treatment VMX-C001.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 16, 2025 by businesswire